Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | STS | P08842 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TCF4 | P15884 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451358 | 0.85 | STS (0.71) | POLBSMN1; SMN2TP53STSL3MBTL1 | |
| SCHEMBL7441195 | 0.83 | SMN1; SMN2 (0.52) | POLBSMN1; SMN2TP53STSL3MBTL1 | |
| SCHEMBL10296034 | 0.83 | STS (0.53) | SMN1; SMN2STSRAB9ANPC1CA12 | |
| SCHEMBL2964425 | 0.83 | PPARG (0.61) | STSALDH1A1KMT2A | |
| SCHEMBL3626199 | 0.83 | CA2 (0.51) | POLBSMN1; SMN2STSL3MBTL1RAB9A | |
| SCHEMBL1050436 | 0.83 | POLB (0.50) | POLBSMN1; SMN2TP53STSL3MBTL1 | |
| SCHEMBL2893033 | 0.82 | CA1 (0.48) | POLBSMN1; SMN2STSL3MBTL1RAB9A | |
| SCHEMBL14526611 | 0.82 | STS (0.53) | POLBSMN1; SMN2STSRAB9ACA12 | |
| SCHEMBL30697344 | 0.82 | STS (0.53) | POLBSMN1; SMN2STSRAB9ACA12 | |
| SCHEMBL27571314 | 0.81 | PARP1 (0.64) | STSCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113316566-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10407376-B2 | Method to prepare phenolics from biomass | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2019-09-10 | — | — | US | disclosed |
| US-20170349529-A1 | Method to Prepare Phenolics from Biomass | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2017-12-07 | — | — | US | disclosed |
| EP-3245186-A1 | METHOD TO PREPARE PHENOLICS FROM BIOMASS | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016114668-A1 | METHOD TO PREPARE PHENOLICS FROM BIOMASS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2016-07-21 | — | — | WO | disclosed |
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407376-B2 | Method to prepare phenolics from biomass | FDPS, DNPH1, HPD | POLB 1330/4885SMN1; SMN2 4838/4885TP53 2149/4885 |
| US-20170349529-A1 | Method to Prepare Phenolics from Biomass | FDPS, DNPH1, HPD | POLB 1330/4885SMN1; SMN2 4838/4885TP53 2149/4885 |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | POLB 4752/4885SMN1; SMN2 2088/4885TP53 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.